Endocrine therapy tolerance as a cancer cell survival mechanism for late recurring breast cancer

内分泌治疗耐受作为晚期复发性乳腺癌的癌细胞生存机制

• 批准号: nhmrc : GNT1138077
• 负责人: Dr Catherine Caldon
• 金额: $ 45.01万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/endocrine-therapy-tolerance-breast-cancer/1348116
• 关键词: Endocrine; therapy; tolerance; cancer; cell

~25% of breast cancer deaths are attributable to cancers that have failed endocrine therapy and recur >5 years after primary diagnosis. These cancers are not well understood because their long latency makes them difficult to study. We have new models of this disease that identify a “therapy tolerant” population, and this is likely to re-emerge to cause late recurrence. Our work could potentially identify new biological tests and therapeutic strategies to treat late recurring breast cancer.

约 25% 的乳腺癌死亡归因于内分泌治疗失败且在初次诊断后 5 年以上复发的癌症。这些癌症尚未得到很好的了解，因为它们的潜伏期长使得研究起来很困难。我们有这种疾病的新模型，可以识别出“治疗耐受”人群，这很可能再次出现，导致晚期复发。我们的工作可能会确定新的生物测试和治疗策略来治疗晚期复发性乳腺癌。